Recombinant CD27 antibody

Catalog No. ABIN7072441

This Rat Monoclonal antibody specifically detects CD27 in FACS, IP and Neut. It exhibits reactivity toward Mouse.

Quick Overview for Recombinant CD27 antibody (ABIN7072441)

Target: CD27 (CD27 Molecule (CD27))

Antibody Type: Recombinant Antibody

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD27 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Neutralization (Neut)

Clone: RM27-3E5

Product Details anti-CD27 Antibody

Purpose: Anti-CD27 [RM27-3E5], Rat IgG2a, kappa

Specificity: This antibody is specific for the extracellular domain of murine CD27, a TNF-receptor superfamily member.

Characteristics:

Original Species of Ab: Rat

Original Format of Ab: IgG2a

Purification: Protein A affinity purified

Immunogen: This antibody was raised by immunising mouse with mouse CD27-human IgG1 Fc fusion protein. Isolated popliteal lymph node cells were then fused with P3U1 myeloma cells to produce stable hybridomas.

Isotype: IgG2a kappa

Application Details

Application Notes: This antibody recognises murine CD27, as confirmed by flow-cytometry and immunoprecipitation analysis (Sakanishi & Yagita, 2010), a member of the TNF-receptor superfamily. The interaction between CD27 and its ligand CD70, which is recognised by anti-CD70 antibody TAN 1-7 (Ab00816), is crucial to regulation of the survival and differentiation of T cells, B cells and NK cells. As a result, RM27-3E5 modulates multiple immune cell types. The original rat IgG2a version of RM27-3E5 did not deplete T cells, NKT or NK cells, but does enhance the proliferation of anti-CD3-stimulated splenic T cells (Sakanishi & Yagita, 2010). In murine models of melanoma, it promotes the persistence of tumour-specific CD8+ T cells within tumours, and reduces levels of PD-1 expression on CD8+ T cells (Roberts et al, 2010). Additionally, anti-CD27 reduces the proportion of FoxP3+ CD4+ T cells in tumours, and enhances the effector activity of IFNγ-secreting, tumour-infiltrating CD8+ T cells and NK cells (Roberts et al, 2010). Finally, anti-CD27 Ab treatment alters murine splenocyte cytokine production, significantly reducing IL-5 and IFN-γ synthesis, and increasing TNF-α production (Sumi et al, 2008). It also significantly suppresses total serum IgE levels, while significantly increasing IgG1 and IgG2a levels. These immune modulatory properties translate into potent anti-tumour effects in mice. Treatment of established murine melanoma with RM27-3E5 (rat IgG2a) resulted in a significant reduction in lung metastases and subcutaneous tumours, through an IFNγ-dependent mechanism mediated by CD8+ T cells and NK cells (Roberts et al, 2010). In murine models of T cell lymphoma, the tumour-specific CTL response induced by RM27-3E5 (rat IgG2a) promoted almost complete regression of tumours, regardless of CD27 expression on tumour cells (Sakanishi & Yagita, 2010). This antibody has been used to identify CD27-expressing cells through flow-cytometry (Koyanagi et al, 2012).

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD27

Target: CD27 (CD27 Molecule (CD27))

Alternative Name: CD27

Background: TNFRS7, CD27 antigen, CD27L receptor, T-cell activation antigen CD27, Tumor necrosis factor receptor superfamily member 7

UniProt: P41272

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints